NCI-2022-06107

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Cemiplimab in Patients with Advanced Cancers

In this Phase 1/2 study, researchers are testing a new treatment called E-602 to see if it is safe and effective for patients with advanced cancers. The study is open to patients who have not responded well to standard treatments. E-602 will be given alone and also in combination with another medication called cemiplimab, which helps the immune system fight cancer. The main goals of the study are to find the highest safe dose of E-602, understand how the body processes the treatment, and see if it can shrink tumors.

Phase 1/2: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05259696

Clinical Trial Site: Columbia

To see all available clinical trials click here.